NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 26 June 2023 (#23)

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

To prepare an application can take 4-18 months, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43

2. Requirement of preliminary data

3. Time to assemble the research team

4. Time available to work on the grant, taking into consideration other responsibilities

5. Time for internal review

*Before starting your application, attend the **1) Generic Grant Writing Workshop** and then the **2) NIH Grant Writing Workshop**.*

Important Notices

NOT-OD-23-149 The Use of Generative Artificial Intelligence Technologies is Prohibited for the NIH Peer Review Process. The purpose of this Notice is to clarify NOT-OD-22-044 on Maintaining Security and Confidentiality in NIH Peer Review: Rules, Responsibilities and Possible Consequences and inform the extramural community that the NIH prohibits NIH scientific peer reviewers from using natural language processors, large language models, or other generative Artificial Intelligence (AI) technologies for analyzing and formulating peer review critiques for grant applications and R&D contract proposals. NIH is revising its Security, Confidentiality, and Non-disclosure Agreements for Peer Reviewers to clarify this prohibition. Reviewers should be aware that uploading or sharing content or original concepts from an NIH grant application, contract proposal, or critique to online generative AI tools violates the NIH peer review confidentiality and integrity requirements.

Successful Sample Applications Demonstrate Good Grantsmanship. One way to hone your grantsmanship skills is to examine well-written examples of successful grant applications. When you do so, remember that your application must also follow the latest official NIH How To Apply SF 424 instructions.

Parent Announcements

NOT-OD-23-105 Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities. Current Key Dates *Expiration Date: May 8, 2023* **Modified Key Dates *Expiration Date:*** *May 8, 2024*
Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- **PA-20-185** NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- **PA-20-184** Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- **PA-20-183** Research Project Grant (Parent R01 Clinical Trial Required)
- **PA-20-200** NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- **PA-20-195** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- **PA-20-194** NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- **PA-20-196** NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest (NOSI)

NOT-AI-23-046 HIV Cure-Related Research in Diverse Populations. This NOSI is to highlight NIAID's interest in HIV cure-related research in diverse cohorts of people living with HIV to determine similarities and differences in the establishment and dynamics of persistent non-subtype B HIV reservoirs, as well as in post-treatment control of viremia.
NIAID encourages applications in basic, preclinical, or clinical research studies using existing human samples to analyze and compare HIV human reservoir establishment, dynamics, persistence, and post-treatment control in diverse cohorts of people living with HIV. The proposed studies should include particular emphasis on the impact of viral subtype, sex, age, coinfections and comorbidities, and geography. Studies including samples from people living with HIV in low- and middle-income countries (LMICs) are encouraged. Clinical trials are not allowed, but the use of existing samples from clinical trials are encouraged, particularly longitudinal samples from participants on ART that underwent a treatment interruption.
NIDDK encourages applications that primarily focuses on HIV-1 reservoirs in anatomical sites relevant to its mission, particularly the gastrointestinal mucosa, liver, kidney, male genital tract, and adipose tissue depots including those at ectopic sites. In addition, prevalent NIDDK-related comorbidities and coinfections can impact the HIV-1 reservoir through inflammatory pathways, metabolic perturbations, or other pathophysiological processes. Therefore, NIDDK is also interested in research on how comorbidities and coinfections within its mission impact HIV-1 reservoir dynamics and immune control.
NIMH encourages HIV-1 cure related research in diverse cohorts of people living with HIV to determine similarities and differences in the establishment and dynamics of persistent non-subtype B reservoirs as well as post treatment control of viremia in the central nervous system (microglia, macrophages, astrocytes)
This Notice applies to due dates on or after **September 7, 2023**, and subsequent receipt dates through **May 7, 2026**. The NOFOs listed or their reissued equivalents must be used for submissions for this initiative.

NOT-AI-23-049 Using Targeted Degradation of Protein and non-Protein Targets for the Development of Novel Anti-Infectives. The purpose of this NOSI is to invite applications for research on the use of targeted protein and nonprotein degradation (e.g., RNA) as it relates to the development of anti-infective strategies against viral, bacterial, and fungal pathogens and/or their toxins (e.g., Lethal and Edema Toxins of *Bacillus anthracis*). Both novel monofunctional (e.g., Molecular Glues) and hetero-bi/tri-functional (e.g., PROTAC or PROTAC-like) strategies will be considered. This notice applies to application receipt dates on or after **October 5, 2023**, and subsequent receipt dates through **July 16, 2026**. The NOFOs listed or their reissued equivalents must be used for submissions for this initiative.

Notice of Funding Opportunity (NOFO)

1. Informatics Tools for the Pangenome (U01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink: RFA-HG-23-026** **Type: U01**
Application Due Date: November 01, 2023; March 03, 2025. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Announcement: This NOFO seeks applications for the development of informatics tools to facilitate uptake and scientific use of the human pangenome reference being developed and maintained by the NHGRI Human Genome Reference Program (HGRP). Emphasis for this RFA will be on development of tools to advance compelling use cases that are relevant to different broad sectors of the genomics community, e.g., clinical, population, and functional genomics. These tools will use pangenome datasets and build on systems developed by the Human Pangenome Coordinating Center (see below), which will support general computational infrastructure for pangenome use. This informatics tools RFA will fund one component of an overall HGRP, which will also include two other components: High Quality Reference Genomes (herein called "Genomes Center"), and a Human Pangenome Coordinating Center (Herein called "Coordinating Center"). (See Companion Funding Opportunities). Awardees under all three RFAs will work collaboratively within a consortium towards production and community adoption of the human pangenome reference.
Budget: NHGRI intends to commit $2M in FY 2024, and a further $2M in FY2026 to fund up to 6 awards. Application budgets are limited to $400,000 direct costs per year, but need to reflect the actual needs of the proposed project. The maximum project period is 3 years.